PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit From Extended Adjuvant Capecitabine in Patients With TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Triple negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine
Clin. Cancer Res 2022 Nov 08;[EPub Ahead of Print], K Asleh, A Lluch, A Goytain, C Barrios, XQ Wang, L Torrecillas, D Gao, M Ruiz-Borrego, S Leung, J Bines, Á Guerrero-Zotano, JÁ García-Sáenz, JM Cejalvo, J Herranz, R Torres, J de la Haba-Rodriguez, F Ayala, H Gómez, F Rojo, TO Nielsen, M MartinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.